Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 831-838

  Fukuchi, Yoshinosuke ^a   Tatsumi, Koichiro ^b   Inoue, Hiromasa ^c   Sakata, Yukinori ^d   Shibata, Kai ^d   Miyagishi, Hideaki ^d   Marukawa, Yasuhiro ^d   Ichinose, Masakazu ^e  

^a JUNTENDO UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d EISAI CO LTD   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

COPD assessment test; COPD exacerbation; Forced expiratory volume in 1 second; Lysozyme

Indexed keywords

BRONCHODILATING AGENT; LYSOZYME; PLACEBO;

ADVERSE OUTCOME; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; COUGHING; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPIROMETRY; SYMPTOM; DISEASE COURSE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

AGED; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MURAMIDASE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84964507665     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S103105     Document Type: Article

References (23)

1. Burgel PR, Nesme-Meyer P, Chanez P, et al; Initiatives Bronchopneumopathie Chronique Obstructive Scientific Committee. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009;135(4):975–982.
2. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153(5):1530–1535.
3. Dajani R, Zhang Y, Taft PJ, et al. Lysozyme secretion by submucosal glands protects the airway from bacterial infection. Am J Respir Cell Mol Biol. 2005;32(6):548–552.
4. Ellison RT 3rd, Giehl TJ. Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest. 1991;88(4):1080–1091.
5. Gordon LI, Douglas SD, Kay NE, Yamada O, Osserman EF, Jacob HS. Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammation. J Clin Invest. 1979;64(1):226–232.
6. Shimizu K, Kondo M, Yonebayashi S, Sakuma Y, Taira Y. Effects of lysozyme chloride (Acdeam®) on foreign materials excretion by tracheal mucociliary transport. Jpn Pharmacol Ther. 1997;25(9):2347–2358.
7. Kayama S, Fukuchi Y, Harasawa M. An experimental study in the influence of age various drugs on ciliary beat frequency. Jpn Pharmacol Ther. 1985;13(2):701–705.
8. Tanaka K, Mikami M, Ishikawa T, et al. The study of lysozyme chloride on the relationship between the chances of symptoms and physiochemical properties of sputum in chronic pulmonary disease. Jpn J Med Pharm Sci. 2005;53(5):581–600.
9. Ohbayashi H, Setoguchi Y, Fukuchi Y, Shibata K, Sakata Y, Arai T. Pharmacological effects of lysozyme on COPD and bronchial asthma with sputum: a randomized, placebo-controlled, cross-over study. Pulm Pharmacol Ther. 2016;37:73–80.
10. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study. Lancet. 2008;371(9629):2013–2018.
11. Zheng JP, Wen FQ, Bai CX, et al; PANTHEON Study Group. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2(3):187–194.
12. Tsuda T, Suematsu R, Kamohara K, et al. Development of the Japanese version of the COPD assessment test. Respir Investig. 2012;50(2):34–39.
13. Agusti A. The path to personalised medicine in COPD. Thorax. 2014;69(9):857–864.
14. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbation of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196–204.
15. Naito S, Tominaga H, Uno J, Dohiguchi Y, Hamaguchi K. The anti-inflammatory effect of lysozyme hydrochloride on rabbits with different doses. Jpn Pharmacol Ther. 1986;14(6):4165–4169.
16. Fukawa K, Irino O, Watanabe A. Pharmacological effects of lysozyme and its reaction with serum proteins. Pharmacometrics. 1981;21(4):587–593.
17. Piatti G, Ambrosetti U, Santus P, Allegra L. Effects of salmeterol on cilia and mucus in COPD and pneumonia patients. Pharmacol Res. 2005;51(2):165–168.
18. Hogg J, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–2653.
19. Nishimura M, Makita H, Nagai K, et al; Hokkaido COPD Cohort Study Investigators. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(1):44–52.
20. Celli BR, Decramer M, Wedzicha JA, et al; ATS/ERS Task Force for COPD. An official American Thoracic Society/European Respiratory Society statement: research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(7):e4–e27.
21. Cazzola M, Hanania NA, MacNee W, Rüdell K, Hackford C, Tamimi N. A review of the most common patient-reported outcomes in COPD – revisiting current knowledge and estimating future challenges. Int J Chron Obstruct Pulmon Dis. 2015;10:725–738.
22. Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD assessment test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203.
23. Hashida S, Ishikawa E, Nakamichi N, Sekino H. Concentration of egg white lysozyme in the serum of healthy subjects after oral administration. Clin Exp Pharmacol Physiol. 2002;29(1–2):79–83.